Loading
Proviva Therapeutics is testing PTX-912, an engineered form of the immune signal IL-2 designed to switch on mainly inside tumours, in an early trial in the United States for people with advanced solid tumours.
Proviva Therapeutics (博致生物) develops cytokine immunotherapies using what it calls a Crossover cytokine prodrug platform, designed to release activity in the tumour microenvironment and limit the systemic toxicity of cytokines. Its lead candidate, PTX-912, is described in its March 2024 Series A announcement as an immune-cell-targeted IL-2 prodrug fusion protein and in its December 2025 Series A+ announcement as a PD-1/IL-2 prodrug fusion protein. PTX-912 is in a first-in-human phase 1a/1b trial in locally advanced or metastatic solid tumours (NCT06190886), sponsored by Proviva Therapeutics, Inc., at US sites including City of Hope and the University of Miami. Financing: an $18 million Series A in March 2024 with Longpan Capital and others, and a Series A+ of over $30 million announced in December 2025, led by OrbiMed. The Chinese operating company is registered in the Shanghai Free Trade Zone and was established in August 2019; OrbiMed's portfolio page also says it was founded in 2019.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A+ · Announced 1 December 2025 as over US$30 million, led by OrbiMed with Hankang Capital, HongShan (Sequoia China) and a corporate fund; exact amount not stated. | 2025 | undisclosed | pharnexcloud.com |
| Series A · Reported 6 March 2024 with participation from 龙磐投资 (Longpan), 恩然创投 and 仙瞳资本. | 2024 | $18M | news.pedaily.cn |
Amounts only where the cited source states them. Rounds without a public source are not listed.
PTX-912 is an experimental immune-stimulating protein from Proviva Therapeutics, in phase 1 trials for advanced solid tumours.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/